UBRELVY® is well established
UBRELVY is well established and tolerable—for patients taking both doses1
Adverse reactions occurring in at least 2% and at a frequency greater than placebo1
| Placebo (n=984) |
UBRELVY 50 mg (n=954) |
UBRELVY 100 mg (n=485) |
|
|---|---|---|---|
| Nausea | 2% | 2% | 4% |
| Somnolence | 1% | 2% | 3% |
| Dry mouth | 1% | <1% | 2% |
Table includes ARs from ACHIEVE I and II.
No cardiovascular warnings
or precautions1
No medication overuse headache
warnings or precautions1
UBRELVY is not a controlled
substance and not shown to be
habit-forming1
The incidence of adverse
reactions was not affected by sex
or age2
No medication overuse headache
warnings or precautions1
Adverse reactions not affected
by sex or age2
Long-term safety established
The long-term safety of UBRELVY was further established in 813 patients in a 52-week, open-label trial, with 31,968 doses given. In these studies, discontinuation rates due to adverse events were 2% to 3%.3
UBRELVY IS THE ONLY GEPANT WITH AN OPTIONAL SECOND DOSE.1,4
Migraine attacks can be unpredictable and no two attacks are the same.5
Patients can take an additional dose of UBRELVY at least 2 hours after the initial dose—there are no medication overuse headache warnings or precautions. The maximum UBRELVY dose in a 24-hour period is 200 mg. The safety of treating more than 8 migraines in a 30-day period has not been established.1
Up next: See dosing